Century Therapeutics Inc (IPSC) Stock Price, Quote & News

Company Profile

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 817 5790

Website: www.centurytx.com

Address:

25 North 38th Street, 11th Floor, Philadelphia, United States

MinskyMoney Dec. 26 at 3:17 PM

$IPSC Market structure is quietly punishing unfocused strategies. Governance alignment should reduce uncertainty over time. Clear execution would attract broader institutional participation. Without validation, volatility will remain persistent.

0 · Reply

AveraveJoeTrader Dec. 26 at 2:29 PM

$IPSC Strong move took this over $1 Looking for this to act as support to continue this higher up the chart..

0 · Reply

nepepe Dec. 24 at 8:29 PM

$IPSC booolish candle

0 · Reply

SwingTradesOnly Dec. 24 at 4:14 PM

$IPSC hit 1.09, secured profits. might go back and re-test EMA(8), might not, still watching.

0 · Reply

ChazzyTrades Dec. 24 at 3:31 PM

$IPSC wants more

0 · Reply

gnarled15 Dec. 24 at 3:28 PM

$IPSC more moon pls

0 · Reply

nepepe Dec. 24 at 3:15 PM

$IPSC 🧬 imminent

0 · Reply

gnarled15 Dec. 24 at 3:12 PM

$IPSC 🏃‍♂️🏃‍♂️

0 · Reply

Lyn30 Dec. 24 at 2:55 PM

$IPSC Destination reached ✅

0 · Reply

SwingTradesOnly Dec. 23 at 9:02 PM

$IPSC hit 1.00 let's go

0 · Reply

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 7:30 AM EST - 6 weeks ago

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 7:00 AM EST - 6 weeks ago

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Oct 14, 2025, 4:01 PM EDT - 2 months ago

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Aug 22, 2025, 8:00 AM EDT - 4 months ago

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:01 PM EDT - 4 months ago

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

May 28, 2025, 4:01 PM EDT - 7 months ago

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 15, 2025, 4:01 PM EDT - 8 months ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:30 PM EDT - 8 months ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Mar 19, 2025, 4:01 PM EDT - 10 months ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Nov 26, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:05 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 20, 2024, 11:07 AM EDT - 1 year ago

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 6:03 PM EST - 1 year ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 9, 2023, 12:00 PM EST - 2 years ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

$Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus$

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Nov 21, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 9, 2023, 7:01 AM EST - 2 years ago

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Aug 9, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Century Therapeutics Announces Leadership Changes

Mar 16, 2023, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 15, 2023, 4:01 PM EDT - 3 years ago

Century Therapeutics to Present at the AACR Annual Meeting 2023

Feb 21, 2023, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at Upcoming Investor Conferences

$Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas$